1
/
of
0
Levero (Levetiracetam) for IV injection
Levero (Levetiracetam) for IV injection
Regular price
₱920.00 PHP
Regular price
Sale price
₱920.00 PHP
Taxes included.
Quantity
Couldn't load pickup availability
Levero (Levetiracetam) is a broad-spectrum anticonvulsant medication formulated for intravenous administration. This injectable solution is indicated for adjunctive therapy in the treatment of partial-onset seizures, myoclonic seizures, and generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam works by modulating neuronal excitability through binding to synaptic vesicle protein SV2A, thereby reducing abnormal neuronal firing without significantly affecting normal neurotransmission.
The IV formulation provides rapid onset of action, making it suitable for acute seizure management and hospital settings where oral administration may not be feasible. Levero is particularly valuable in critical care environments, perioperative seizure prophylaxis, and emergency epilepsy treatment protocols. The intravenous route ensures predictable bioavailability and enables precise dose titration for optimal therapeutic control.
Key clinical advantages include minimal hepatic metabolism, allowing safe use in patients with liver impairment, and a favorable pharmacokinetic profile with predictable elimination. Levero demonstrates efficacy across multiple seizure types and is well-tolerated as monotherapy or adjunctive treatment in polypharmacy regimens. The medication does not require therapeutic drug monitoring, simplifying clinical management.
Suitable for adult patients and pediatric populations where IV anticonvulsant therapy is indicated. Levero supports seizure control and neurological stability, reducing the risk of status epilepticus and related complications. Administered under medical supervision in clinical settings, ensuring appropriate dosing and safety protocols for optimal patient outcomes.
The IV formulation provides rapid onset of action, making it suitable for acute seizure management and hospital settings where oral administration may not be feasible. Levero is particularly valuable in critical care environments, perioperative seizure prophylaxis, and emergency epilepsy treatment protocols. The intravenous route ensures predictable bioavailability and enables precise dose titration for optimal therapeutic control.
Key clinical advantages include minimal hepatic metabolism, allowing safe use in patients with liver impairment, and a favorable pharmacokinetic profile with predictable elimination. Levero demonstrates efficacy across multiple seizure types and is well-tolerated as monotherapy or adjunctive treatment in polypharmacy regimens. The medication does not require therapeutic drug monitoring, simplifying clinical management.
Suitable for adult patients and pediatric populations where IV anticonvulsant therapy is indicated. Levero supports seizure control and neurological stability, reducing the risk of status epilepticus and related complications. Administered under medical supervision in clinical settings, ensuring appropriate dosing and safety protocols for optimal patient outcomes.